Barclays PLC增持昭衍新药(06127)约327.98万股每股作价约24.25港元

智通财经07-20 19:32

智通财经APP获悉，香港联交所最新资料显示，7月15日，Barclays PLC增持昭衍新药(06127)327.982万股，每股作价24.2508港元，总金额约为7953.83万港元。增持后最新持股数目约为728.53万股，最新持股比例为6.12%。

补充资料：Notifiable interest first occurred due to increase in Equity shares. BBPLCs interests in 2068664 shares long and short and BCSLs interests in 1295444 shares long and 773220 shares short as disclosed at box 22 pertain to an intragroup hedge between BBPLC and BCSL. Interests arising under the hedge are not double counted at BPLCs level.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2652890218?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-20 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652890218","market":"hk","top_or_hot":-1,"title":"Barclays PLC增持昭衍新药(06127)约327.98万股 每股作价约24.25港元","media":"智通财经","content":"<html><body><p>智通财经APP获悉，香港联交所最新资料显示，7月15日，Barclays PLC增持<a href=\"https://laohu8.com/S/603127\">昭衍新药</a>(06127)327.982万股，每股作价24.2508港元，总金额约为7953.83万港元。增持后最新持股数目约为728.53万股，最新持股比例为6.12%。</p><p>补充资料：Notifiable interest first occurred due to increase in Equity shares. BBPLCs interests in 2068664 shares long and short and BCSLs interests in 1295444 shares long and 773220 shares short as disclosed at box 22 pertain to an intragroup hedge between BBPLC and BCSL. Interests arising under the hedge are not double counted at BPLCs level.</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Barclays PLC增持昭衍新药(06127)约327.98万股 每股作价约24.25港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBarclays PLC增持昭衍新药(06127)约327.98万股 每股作价约24.25港元\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP获悉，香港联交所最新资料显示，7月15日，Barclays PLC增持<a href=\"https://laohu8.com/S/603127\">昭衍新药</a>(06127)327.982万股，每股作价24.2508港元，总金额约为7953.83万港元。增持后最新持股数目约为728.53万股，最新持股比例为6.12%。</p><p>补充资料：Notifiable interest first occurred due to increase in Equity shares. BBPLCs interests in 2068664 shares long and short and BCSLs interests in 1295444 shares long and 773220 shares short as disclosed at box 22 pertain to an intragroup hedge between BBPLC and BCSL. Interests arising under the hedge are not double counted at BPLCs level.</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1469911.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06127","symbol_name":"昭衍新药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1469911.html","article_id":"2652890218","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652890218","pubTimestamp":1784547178,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，香港联交所最新资料显示，7月15日，Barclays PLC增持昭衍新药327.982万股，每股作价24.2508港元，总金额约为7953.83万港元。增持后最新持股数目约为728.53万股，最新持股比例为6.12%。补充资料：Notifiable interest first occurred due to increase in Equity shares. BBPLCs interests in 2068664 shares long and short and BCSLs interests in 1295444 shares long and 773220 shares short as disclosed at box 22 pertain to an intragroup hedge between BBPLC and BCSL. Interests arising under the hedge are not double counted at BPLCs level.","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603127":"昭衍新药","06127":"昭衍新药","EWH":"香港ETF-iShares MSCI","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","BK0216":"研究试验"},"translate_title":"Barclays PLC increased its holdings of Zhaoyan New Drug (06127) by approximately 3.2798 million shares at a price of approximately HK$24.25 per share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603127":1.5,"06127":1.5,"EWH":1.5},"content_text":"智通财经APP获悉，香港联交所最新资料显示，7月15日，Barclays PLC增持昭衍新药(06127)327.982万股，每股作价24.2508港元，总金额约为7953.83万港元。增持后最新持股数目约为728.53万股，最新持股比例为6.12%。补充资料：Notifiable interest first occurred due to increase in Equity shares. BBPLCs interests in 2068664 shares long and short and BCSLs interests in 1295444 shares long and 773220 shares short as disclosed at box 22 pertain to an intragroup hedge between BBPLC and BCSL. Interests arising under the hedge are not double counted at BPLCs level.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652890218","isCrawlerRequest":true}

Barclays PLC增持昭衍新药(06127)约327.98万股 每股作价约24.25港元

精彩评论

Barclays PLC增持昭衍新药(06127)约327.98万股每股作价约24.25港元